Security
Veru Inc. Common Stock · VERU
VERUNASDAQCommon stockCurrentCIK 863894Updated Oct 6, 2026
Name history
FEMALE HEALTH CO · through Aug 1, 2017
VERU price & chart
Loading TradingView…
NASDAQ:VERU on TradingView ↗About the company
Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and oncology. The Company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass to improve body composition and physical function which is expected to result in clinically meaningful incremental weight reduction versus GLP-1 RA therapy alone. Based on previous and new preclinical and clinical studies, sabizabulin, an oral novel microtubule targeting agent that targets downstream components of the KRAS signaling pathway, has demonstrated the potential to become the next treatment for KRAS-driven metastatic pancreatic cancer resistant to the recent FDA approved daraxonrasib multi-selective KRAS inhibitor therapy. Accordingly, the Company plans to pursue a Phase 2b clinical study to evaluate the efficacy and safety of sabizabulin in patients for the treatment of metastatic pancreatic c…
In the news
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day ↗
Recent filings
Other Events
Items 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Entry into a Material Definitive Agreement
Items 1.01, 9.01
424B5 filing
Show 5 more recent filings
Other Events
Items 8.01
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 37,027,670Source | 27,330,758Source | 64,631,654Source | 43,082,726Source | 32,671,943Source | 71,800,359Source | 47,567,030Source | 39,828,594Source | 29,835,719Source | 60,418,772Source | 60,204,082Source | 136,126,017Source |
| Property, Plant and Equipment, NetUSD | 280,227Source | 393,381Source | 1,491,129Source | 308,421Source | 422,712Source | 1,534,196Source | 336,615Source | 452,043Source | 364,808Source | 1,284,654Source | — | 1,185,766Source |
| GoodwillUSD | 6,878,932Source | 6,878,932Source | 6,878,932Source | 6,878,932Source | 6,878,932Source | 6,878,932Source | 6,878,932Source | 6,878,932Source | 6,878,932Source | 6,878,932Source | — | 6,878,932Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | 0Source | — | 3,977,381Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 23,880,142Source | 15,010,154Source | 29,150,879Source | 27,596,820Source | 20,018,392Source | — | 32,991,417Source | 26,607,002Source | 15,794,562Source | 24,916,285Source | — | — |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 1,642,063Source | — | — | 2,785,331Source | — | — | — | 3,960,305Source | — | 3,550,895Source |
| Inventory, NetUSD | — | — | 4,942,246Source | — | — | 4,804,665Source | — | — | — | 4,144,179Source | — | 8,618,944Source |
| Assets, CurrentUSD | 27,228,327Source | 16,193,177Source | 38,476,141Source | 33,355,476Source | 21,377,764Source | 45,137,301Source | 36,806,716Source | 28,380,136Source | 18,915,118Source | 35,223,224Source | 32,667,682Source | 104,769,474Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,436,799Source | 1,183,023Source | 1,615,254Source | 2,590,923Source | 1,359,372Source | 1,884,684Source | 1,410,072Source | 1,773,134Source | 595,251Source | 1,783,084Source | — | 1,964,373Source |
| Operating Lease, Right-of-Use AssetUSD | 2,342,186Source | 2,875,672Source | 3,756,812Source | 2,479,348Source | 3,002,939Source | 3,947,417Source | 2,613,920Source | 3,127,887Source | 2,746,014Source | 3,561,773Source | — | 4,786,915Source |
| Other Assets, NoncurrentUSD | 297,998Source | 989,596Source | 1,320,328Source | 60,549Source | 989,596Source | 1,320,142Source | 930,847Source | 989,596Source | 930,847Source | 1,129,952Source | — | 1,561,564Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 8,651,430Source | 11,986,125Source | 27,011,198Source | 8,297,105Source | 11,624,710Source | 26,590,715Source | 10,442,989Source | 13,201,605Source | 11,503,049Source | 28,102,060Source | 39,557,846Source | 55,287,381Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | — | 0Source | 0Source | 0Source | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 172,687Source | 148,688Source | 1,485,676Source | 162,687Source | 1,487,676Source | 1,485,649Source | 162,687Source | 1,485,676Source | 148,687Source | 1,485,676Source | — | 826,926Source |
| Additional Paid in CapitalUSD | 368,368,133Source | 341,751,971Source | 330,561,916Source | 367,799,164Source | 338,782,763Source | 327,182,257Source | 367,396,452Source | 336,462,900Source | 343,286,502Source | 333,788,795Source | — | 253,974,032Source |
| Retained Earnings (Accumulated Deficit)USD | -332,357,975Source | -318,749,421Source | -286,039,012Source | -325,369,625Source | -311,416,601Source | -275,070,138Source | -322,628,493Source | -303,514,982Source | -317,295,914Source | -294,569,635Source | -248,636,094Source | -165,574,198Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 0Source | 0Source | -581,519Source | 0Source | 0Source | -581,519Source | 0Source | 0Source | 0Source | -581,519Source | — | -581,519Source |
| Stockholders' Equity Attributable to ParentUSD | 28,376,240Source | 15,344,633Source | 37,620,456Source | 34,785,621Source | 21,047,233Source | 45,209,644Source | 37,124,041Source | 26,626,989Source | 18,332,670Source | 32,316,712Source | 20,646,236Source | 80,838,636Source |
| Liabilities and EquityUSD | 37,027,670Source | 27,330,758Source | 64,631,654Source | 43,082,726Source | 32,671,943Source | 71,800,359Source | 47,567,030Source | 39,828,594Source | 29,835,719Source | 60,418,772Source | 60,204,082Source | 136,126,017Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 6,155,872Source | 6,682,015Source | 10,620,035Source | 5,388,843Source | 5,619,320Source | 9,566,363Source | 7,127,700Source | 6,348,228Source | 7,785,160Source | 11,867,968Source | 26,435,863Source | 41,437,629Source |
| Operating Lease, Liability, CurrentUSD | 775,157Source | 753,400Source | 1,038,795Source | 770,257Source | 747,951Source | 1,043,029Source | 764,590Source | 742,449Source | 758,946Source | 1,065,497Source | — | 957,085Source |
| Accounts Payable, CurrentUSD | 1,709,689Source | 2,538,724Source | 3,018,334Source | 2,071,710Source | 2,205,474Source | 2,464,135Source | 1,516,138Source | 1,994,645Source | 3,121,448Source | 3,036,841Source | 15,944,004Source | 22,003,394Source |
| Operating Lease, Liability, NoncurrentUSD | 1,907,735Source | 2,500,736Source | 3,074,721Source | 2,063,089Source | 2,640,965Source | 3,262,818Source | 2,212,767Source | 2,775,190Source | 2,358,018Source | 2,921,380Source | — | 4,093,667Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 81,067Source |
| Other Liabilities, NoncurrentUSD | 587,823Source | 2,803,374Source | 4,739,375Source | 845,173Source | 3,364,425Source | 4,986,250Source | 1,102,522Source | 4,078,187Source | 1,359,871Source | 4,461,920Source | — | 18,577Source |
| Additional Financial Items | ||||||||||||
| Accounts Receivable, after Allowance for Credit LossUSD | — | — | — | — | — | 2,785,331Source | — | — | — | — | — | 3,550,895Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 395,736Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 28,193Source | 64,870Source | 152,105Source | 268,177Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 757,605Source | 2,674,105Source | 8,102,177Source | 13,644,405Source | 17,918,603Source | 11,242,423Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 0Source | 657,253Source | 657,253Source | -546,203Source | 4,153,327Source | -4,537,829Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 0Source | -863,928Source | -863,928Source | -986,108Source | -648,628Source | 3,126,710Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,862,659Source | -1,282,454Source | -2,760,287Source | -5,432,411Source | -9,072,222Source | 18,593,623Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 0Source | -1,915Source | -1,916Source | 367,182Source | 177,499Source | 76,206Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -6,169,490Source | -11,332,987Source | -30,043,088Source | -21,682,333Source | -88,013,814Source | -47,505,004Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 17,245,315Source | 25,142,976Source | 146,214Source | 6,334,300Source | 4,266,948Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 1,083Source | 1,083Source | 158,322Source | 665,700Source | 733,052Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 23,366,345Source | -4,221,611Source | -4,221,611Source | 36,826,910Source | 11,114,333Source | 1,069,196Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 17,196,855Source | 1,690,717Source | -9,121,723Source | 15,290,791Source | -70,565,181Source | -42,168,860Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 0Source | 332,826Source | 332,826Source | 704,600Source | 554,818Source | 2,620,609Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 78,548Source | 368,820Source | 247,361Source | 422,135Source |
| Additional Financial Items | ||||||||||||
| Accretion ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 4,368,798Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | 577,969Source | 1,669,428Source | 402,712Source | 2,223,843Source | 757,605Source | 2,674,105Source | 8,102,177Source | 13,644,405Source | 17,918,603Source | 11,242,423Source |
| Amortization of Deferred ChargesUSD | — | — | — | — | — | — | — | 0Source | 0Source | 164,313Source | — | — |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 71,000Source | 71,000Source |
| DepreciationUSD | — | — | 28,000Source | 29,000Source | 28,000Source | 29,000Source | 28,000Source | 29,000Source | 100,000Source | 300,000Source | 198,000Source | 138,000Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | — | 0Source | 484,615Source | 0Source | 974,303Source | 0Source | 695,216Source | 10,780,290Source | 1,222,908Source | 5,723,623Source | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | 108,740Source | 0Source | 1,976,872Source | 0Source | -120,078Source | -349,078Source | -323,773Source | -176,077Source | — | — |
| Gain (Loss) on Disposition of BusinessUSD | — | — | — | — | — | — | 0Source | -4,204,435Source | -4,103,817Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | 0Source | -184,267Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 8,624,778Source | 8,624,778Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 3,361,013Source | 5,010,528Source | 4,073,185Source | 5,164,433Source | 4,079,833Source | 5,227,113Source | 19,942,747Source | — | — | — |
| GoodwillUSD | — | — | 6,878,932Source | 6,878,932Source | 6,878,932Source | 6,878,932Source | 6,878,932Source | 6,878,932Source | 6,878,932Source | 6,878,932Source | 6,878,932Source | 6,878,932Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | 0Source | 3,900,000Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | -6,988,350Source | -7,323,101Source | -3,092,550Source | -7,852,393Source | -5,332,579Source | -1,809,903Source | -15,681,257Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | 0Source | -9,719Source | 351,418Source | -49,226Source | 0Source | -7,135,444Source | -7,045,022Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 725,101Source | 480,206Source | 236,397Source |
| InterestExpenseNonoperatingUSD | — | — | — | — | — | — | — | — | — | 607,470Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | -72,831Source | 1,566,830Source | 185,499Source | 82,019Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -6,988,350Source | -7,332,820Source | -2,741,132Source | -7,901,619Source | -5,332,579Source | -8,945,347Source | -22,726,279Source | -37,801,426Source | -93,152,692Source | -83,776,020Source |
| Nonoperating Income (Expense)USD | — | — | 725,331Source | 223,375Source | 4,126,418Source | 269,839Source | 91,436Source | 8,438,824Source | 9,069,385Source | -160,928Source | 1,109,730Source | -316,063Source |
| Operating ExpensesUSD | — | — | 7,713,681Source | 8,031,091Source | 7,218,968Source | 9,096,535Source | 5,424,015Source | 10,943,943Source | 35,530,932Source | 43,992,282Source | 107,071,767Source | 113,814,948Source |
| Other Nonoperating Income (Expense)USD | — | — | 179,202Source | 223,375Source | 195,002Source | 269,839Source | 211,514Source | 163,124Source | 768,380Source | 861,619Source | 573,771Source | 495,735Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 0Source | 3,280Source | 389,058Source | 1,078,289Source |
| Unrealized Gain (Loss) on DerivativesUSD | — | — | — | — | — | — | 0Source | -3,138,316Source | -3,138,316Source | -239,000Source | — | — |
| Equity Securities, FV-NI, Gain (Loss) | — | — | —Source | —Source | —Source | —Source | — | — | — | — | — | — |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | —Source | —Source | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 0Source | — | 0Source | — | — | — | 16,886,419Source | 16,296,958Source | 39,354,352Source |
| Cost of RevenueUSD | — | — | — | — | — | — | — | — | — | 11,032,442Source | 8,731,030Source | 8,762,964Source |
| Selling, General and Administrative ExpenseUSD | — | — | — | 5,010,528Source | — | 5,164,433Source | — | 5,227,113Source | — | 31,184,097Source | 48,057,834Source | 43,168,845Source |
| Operating Income (Loss)USD | — | — | -7,713,681Source | -7,546,476Source | -7,218,968Source | -8,122,232Source | -5,424,015Source | -10,248,727Source | -24,750,642Source | -36,915,397Source | -93,782,216Source | -83,223,560Source |
| Other Nonoperating Income (Expense)USD | — | — | 179,202Source | 223,375Source | 195,002Source | 269,839Source | 211,514Source | 163,124Source | 768,380Source | 861,619Source | 573,771Source | 495,735Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -92,672,486Source | -83,539,623Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 725,101Source | 480,206Source | 236,397Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -6,988,350Source | -7,332,820Source | -2,741,132Source | -7,901,619Source | -5,332,579Source | -8,945,347Source | -22,726,279Source | -37,801,426Source | -93,152,692Source | -83,776,020Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.3Source | -0.5Source | -0.12Source | -0.54Source | -0.26Source | -0.61Source | -1.55Source | -0.28Source | -1.1Source | -1.05Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | — | — | — | — | — | — | -1.1Source | -1.05Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 23,050,320Source | 14,657,777Source | 23,050,320Source | 14,638,614Source | 20,311,190Source | 14,638,392Source | 14,646,294Source | 134,875,016Source | 84,973,382Source | 80,122,526Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | — | — | — | — | — | — | 84,973,382Source | 80,122,526Source |
| Interest Expense (non-operating)USD | — | — | — | — | — | — | — | — | — | 607,470Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 71,000Source | 71,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 357,919Source | 302,707Source | 160,191Source |
| General and Administrative ExpenseUSD | — | — | 3,361,013Source | 5,010,528Source | 4,073,185Source | 5,164,433Source | 4,079,833Source | 5,227,113Source | 19,942,747Source | — | — | — |
| Gross ProfitUSD | — | — | — | — | — | — | — | — | — | 5,853,977Source | 7,565,928Source | 30,591,388Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | -6,988,350Source | -7,323,101Source | -3,092,550Source | -7,852,393Source | -5,332,579Source | -1,809,903Source | -15,681,257Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | -0.3Source | -0.5Source | -0.13Source | -0.54Source | -0.26Source | -0.12Source | -1.07Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | 0Source | -9,719Source | 351,418Source | -49,226Source | 0Source | -7,135,444Source | -7,045,022Source | — | — | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 2,427,041Source | 4,368,798Source |
| Nonoperating Income (Expense)USD | — | — | 725,331Source | 223,375Source | 4,126,418Source | 269,839Source | 91,436Source | 8,438,824Source | 9,069,385Source | -160,928Source | 1,109,730Source | -316,063Source |
| Operating ExpensesUSD | — | — | 7,713,681Source | 8,031,091Source | 7,218,968Source | 9,096,535Source | 5,424,015Source | 10,943,943Source | 35,530,932Source | 43,992,282Source | 107,071,767Source | 113,814,948Source |
| Research and Development ExpenseUSD | — | — | 4,352,668Source | 3,020,563Source | 3,145,783Source | 3,932,102Source | 1,344,182Source | 5,716,830Source | 15,588,185Source | 12,808,185Source | 51,202,219Source | 70,646,103Source |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | —Source | —Source | —Source | —Source | — | — | — | — | — | — |
Offerings
Registration 333-294909
Registration 333-294911
Filing attachments
d543118dex991.htm · 8-K · 2026-09-08
EX-99.1 2 d543118dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE ™ ) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial - New positive preclinical studies show that sabizabulin can o…
Read attachment ↗d123580dex991.htm · 8-K · 2026-08-10
EX-99.1 2 d123580dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress - Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - - Phase 2b PLATEAU clinical trial interim …
Read attachment ↗d114190dex991.htm · 8-K · 2026-05-13
EX-99.1 2 d114190dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress - Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027 - - Company to host confe…
Read attachment ↗d84893dex413.htm · S-3 · 2026-04-07
Exhibit 4.13 VERU INC. and [_________________________] as Trustee Guaranteed to the extent set forth therein by the Guarantors named herein. INDENTURE dated as of TABLE OF CONTENTS Page Article 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 …
Read attachment ↗d218771dex991.htm · 8-K · 2026-02-11
Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress - Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter - - Company to host conference call and webcast today at 8:00 a.m. ET - MIAMI, FL - February 11,…
Read attachment ↗d55858dex991.htm · 8-K · 2025-12-17
EX-99.1 2 d55858dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress - Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA - - Incremental weight loss is an acceptable appr…
Read attachment ↗